In a report released today, Daniel Ives from Wedbush maintained a Hold rating on DocuSign (DOCU – Research Report), with a price target of $80.00. The company’s shares closed last Thursday at $93.88, close to its 52-week low of $90.90.
According to TipRanks.com, Ives is a top 100 analyst with an average return of 24.6% and a 63.5% success rate. Ives covers the Technology sector, focusing on stocks such as SailPoint Technologies Holdings, Palo Alto Networks, and CyberArk Software.
DocuSign has an analyst consensus of Moderate Buy, with a price target consensus of $140.38, a 47.9% upside from current levels. In a report issued on March 7, UBS also maintained a Hold rating on the stock with a $110.00 price target.
See the top stocks recommended by analysts >>
Based on DocuSign’s latest earnings release for the quarter ending October 31, the company reported a quarterly revenue of $545 million and GAAP net loss of $5.68 million. In comparison, last year the company earned revenue of $383 million and had a GAAP net loss of $58.49 million.
Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 2003 and headquarterd in California, DocuSign, Inc. is a cloud-based electronic signature solutions name that helps companies and individuals to manage electronic agreements. The company automates manual, paper-based processes, allowing users to manage all aspects of documented business transactions including identity management, authentication, digital signature, forms and data collection, collaboration, workflow automation and storage.
Read More on DOCU:
- H.C. Wainwright Sticks to Its Buy Rating for Seanergy Maritime (SHIP)
- Meta Allows Hate Speech Against Russians Invading Ukraine — Report
- Oracle (ORCL): New Buy Recommendation for This Technology Giant
- Needham Thinks OncoCyte’s Stock is Going to Recover
- Analysts’ Opinions Are Mixed on These Financial Stocks: Deutsche Bank AG (DB) and MarketWise (MKTW)
